Hero Image

Obesity is a function of biology.

ERX Pharmaceuticals Inc. is developing first-in-class leptin sensitizers for the treatment of obesity and related diseases based on a new understanding of the science of obesity.
Learn More
obese man smiling and talking on phone

Obesity

ERX is developing first-in-class leptin sensitizers to address unmet needs in the treatment of obesity.

Learn More
Metabolic Diseases

Metabolic Diseases

Insensitivity to leptin signaling contributes to a range of metabolic diseases, which may be addressable by leptin sensitizers.

Learn More
Hypothalamus Extended
37 catens outline copyCreated with Sketch.

Research + Development

Targeting Leptin Resistance

Leptin signaling plays a critical role in the body’s regulation of food intake and energy expenditure. ERX believes that improving leptin sensitivity can yield significant clinical benefits across a range of metabolic diseases, including obesity.
Learn more
dna-outline-94Created with Sketch.

Pipeline

Drug Discovery and Development

ERX has several drug candidates in the pipeline, from ERX-1000 currently in the clinic, to additional compounds in preclinical or discovery stages.
View Pipeline
Board meeting

Scientific Advisory Board

ERX is supported by an internationally renowned group of engaged scientific advisors who are experts in the fields of leptin biology and obesity drug discovery.

Learn More
news

News & Events

May 2019
ERX Pharmaceuticals Announces Appointment of Chief Medical Officer Barbara Troupin, MD, MBA and Chief Financial Offer Jonathan Lieber, MBA.

LEARN MORE